Skip to Main Content
Phase II-III

Efficacy & Safety of Risankizumab in Subjects with Moderately to Severely Active Ulcerative Colitis

  • Study HIC#:2000026943
  • Last Updated:01/13/2022

Yale is participating in this phase III research study that is testing a new medication (Risankziumab) for Ulcerative Colitis (UC)

You may qualify if you:

  • Are between the ages of 18-80
  • Have been diagnosed with UC within the past 90 days
  • Are currently having UC symptoms
  • Have tried medication for UC but still have symptoms
  • Age16 years - 80 years
  • GenderBoth
  • Start Date07/22/2021
  • End Date09/23/2022

Eligibility Criteria

You may qualify if you:

  • Are between the ages of 18-80
  • Have been diagnosed with UC within the past 90 days
  • Are currently having UC symptoms
  • Have tried medication for UC but still have symptoms

Principal Investigator

Sub-Investigator

For more information about this study, contact:

Or contact the Help us Discover team on: